髋部骨折患者抗骨质疏松药物的配药使用情况:我们能否做得更好?
该研究基于丹麦多学科髋部骨折登记系统,纳入2005-2015年65岁及以上新发髋部骨折患者65,011例,计算骨折前一年和骨折后一年抗骨质疏松药物配药率,并计算骨折后一年累积配药发生率。结果显示骨折前配药率在7%至12%之间,骨折后一年累积配药发生率从2005年16%降至2010年13%后升至20%,各日历年骨折后总体配药率均低于22%,不足三分之一患者有配药。
要点
- 丹麦髋部骨折患者骨折前一年抗骨质疏松药物配药率仅7%至12%。
- 骨折后一年累积配药发生率从2005年16%降至2010年13%再升至20%。
- 各日历年骨折后总体配药率均低于22%,不足三分之一患者有配药。
核心结论
- 不足三分之一的髋部骨折患者在骨折后一年内有过抗骨质疏松药物配药。
- 研究期间骨折后配药仅略有增加,且不受患者性别、年龄和合并症影响。
研究设计与样本
- 基于丹麦多学科髋部骨折登记系统的 population-based 注册数据研究,纳入2005-2015年65岁及以上新发髋部骨折患者65,011例。
- 计算每个骨折诊断日历年的骨折前一年和骨折后一年抗骨质疏松药物(双膦酸盐、雷奈酸锶、地舒单抗、选择性雌激素受体调节剂或特立帕肽中至少一次配药)使用患病率。
- 对骨折前一年无配药者,计算骨折后一年累积使用发生率,并将死亡作为竞争风险处理。
- 按性别、年龄和合并症进行分层分析。
主要发现
- 骨折前抗骨质疏松药物使用患病率在7%至12%之间,从2005年至2015年略有增加。
- 骨折后一年累积使用发生率从2005年16%下降至2010年13%,此后上升至20%。
- 每个性别、年龄组和合并症分层均呈现相似模式。
- 所有日历年中骨折后总体使用患病率均低于22%。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: Although Scandinavian countries have the highest incidence of hip fracture in the world, trends in anti-osteoporosis medication use have not been studied. We found less than one-third of Danish hip fracture patients had dispensing of anti-osteoporosis medication over a 10-year period using routinely collected data from population-based registries. INTRODUCTION: To examine trend in dispensing of anti-osteoporosis medication before and after hip fracture surgery in Denmark over a 10-year period using routinely collected data from population-based registries. METHODS: From the Danish Multidisciplinary Hip Fracture Registry, we included 65,011 patients aged 65 years or older with an incident hip fracture in 2005-2015. We calculated, for each calendar year of hip fracture diagnosis, the prevalence of use of anti-osteoporosis medication (at least one dispensing of bisphosphonates, strontium ranelate, denosumab, selective estrogen receptor modulators, or teriparatide) in the year before and in the year following hip fracture diagnosis. Among those without a dispensing in the year before hip fracture, we computed 1-year cumulative incidence of use following hip fracture. We treated death as a competing risk and stratified the analysis on sex, age, and comorbidity. RESULTS: The prevalence of use before hip fracture varied between 7 and 12%, increasing slightly from 2005 to 2015. The cumulative incidence of use following hip fracture decreased from 16% in 2005 to 13% in 2010, whereupon it increased to 20%. A similar pattern was seen with each stratum of sex, age groups, and comorbidity. The overall prevalence of use after hip fracture was below 22% in all calendar years. CONCLUSIONS: Less than one-third of hip fracture patients had dispensing of anti-osteoporosis medication up to 1 year after hip fracture. We observed only a slight increase in dispensing after hip fracture over the study period, irrespective of patient sex, age, and comorbidity at the time of hip fracture.
引用
- Kristensen PK, Ehrenstein V, Shetty N, et al. Use of anti-osteoporosis medication dispensing by patients with hip fracture: could we do better? Osteoporos Int. 2019. PMID: 31263921. doi:10.1007/s00198-019-05066-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。